INO falls 18% on positive phase I COVID-19 trials – where to next for investors?

Inovio Pharmaceuticals (NASDAQ: INO), last week’s COVID-19 spectacle has now capitulated investors into no mans land after falling after positive Phase I data. It seems strange right, investors were backing INO with the expectation of positive phase I trials. INO fulfilled the expectation yet the bears decided to take the biotech to the woodshed. The […]

INO’s COVID-19 vaccine receives $71 million in government funding – how high can the INO stock go?

The COVID-19 vaccine market was fading as economies began to recover. However, the insurgence of new coronavirus cases and deaths is causing investors to gravitate towards COVID-19 vaccine frontrunners Moderna (NASDAQ: MRNA), Novavax (NASDAQ: NVAX), and Inovio Pharmaceuticals (NASDAQ: INO). It makes logical sense that investors rally behind the vaccine companies. Especially as they have […]